Clinical trial
Effects of ISIS 113715 on Insulin Sensitivity, Glucose, and Lipid Metabolism and…
NCT00330200 · Ionis Pharmaceuticals, Inc., Industry · Terminated
Key facts
| NCT number | NCT00330200 |
|---|---|
| Title | Effects of ISIS 113715 on Insulin Sensitivity, Glucose, and Lipid Metabolism and Energy Expenditure in Type 2 Diabetics |
| Official title | A Randomized, Double-Blind, Placebo-Controlled Study to Examine the Effects of ISIS 113715 Monotherapy on Insulin Sensitivity, Glucose and Lipid Metabolism and Energy Expenditure in Subjects With Type 2 Diabetes Mellitus |
| Lead sponsor | Ionis Pharmaceuticals, Inc., Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Type 2 Diabetes Mellitus |
| Intervention type | Drug |
| Interventions | ISIS 113715 |
| Enrollment | 2 |
| Start date | Nov 1, 2005 |
| Primary completion | Mar 1, 2007 |
| Completion | Mar 1, 2007 |
| First posted | May 26, 2006 |
| Last update posted | Dec 5, 2022 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: